Trulicity is a GLP-1 receptor agonist. It increases intracellular cAMP in beta cells leading to glucose-dependent insulin release. It also decreases glucagon secretion and slows gastric emptying.
Trulicity is supplied as a solution for subcutaneous injection. The recommended initiating dose is 0.75 mg once weekly. The maximum recommended dose is 1.5 mg once weekly. Administered once weekly, any time of day, with or without food. Trulicity should be injected subcutaneously in the abdomen, thigh, or upper arm.